Isoeugenol Inhibits Sphingosine Kinase 1 (SphK1) and Induces Cytotoxicity in Breast Cancer Cells
Abstract
Background: Sphingosine kinase 1 (SphK1) is considered as a critical factor as it controls sphingolipid metabolism and promotes cell survival. Targeting SphK1 with small natural compounds presents a promising therapeutic approach for breast cancer, as these compounds may have the ability to inhibit SphK1 activity, reduce tumor growth, and enhances cytotoxicity, potentially paving the way for new treatment approaches in cancer.
Methods: This study employed in-silico and in-vitro methods to identify the potent inhibitor of SphK1. Molecular docking was used to determine the binding affinity and molecular interactions of protein-ligand complex. Other in-silico methods namely SwissTargetPrediction and PASS analysis were used to determine the pharmacological potential of the lead compound. The MTT assay was conducted to evaluate the cytotoxic effects of isoeugenol, as well as its impact on the expression, protein levels, and activity of SphK1 in MCF-7 breast cancer cells.
Results: Isoeugenol was found as a potent small molecule with highest binding affinity among resveratrol and its structural analogues with SphK1. Results of the molecular docking showed binding affinity of -9.3 kcal/mol of isoeugenol with SphK1, Analysis of the docked isoeugenol-SphK1 complex revealed stable interactions ligand and target protein. Further, results of SwissTargetPrediction analysis showed that isoeugenol has broad pharmacological associations with targeting different proteins and enzymes, which are considered as key factors in various biochemical and molecular pathways, including associated with anticancer processes. MTT assay revealed a significant, dose- and time-dependent decrease in cell viability (both p<0.001). Viability declined progressively at 24, 36, and 48 h, with the effect persisting without further significant change at 60 and 72 h. Further, the IC50 dose of isoeugenol was found to be 102 µM, this concentration was used for further experiments. MCF-7 cells exposed to IC50 dose of isoeugenol showed significantly decreased SphK1 mRNA expression, SphK1 protein levels, and SphK1 kinase activity compared to untreated cells.
Conclusion: The findings of the current study reflect the therapeutic potential of isoeugenol and suggest that inhibition of SphK1 by this small molecule may pave the way for cancer therapeutics, including breast cancer.
Keywords:
Breast cancer, Inhibitor, Isoeugenol, Molecular docking, Sphingosine kinase 1 (SphK1)Full Text:
PDFReferences
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, (2024); 74(3): 229-263.
Obidiro O, Battogtokh G, Akala EO. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, (2023); 15(7): 1796.
Hurvitz SA, Hu Y, O’Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews, (2013); 39(3): 219-229.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of Hematology & Oncology, (2022); 15(1): 121.
Tufail M, Cui J, Wu C. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. American Journal of Cancer Research, (2022); 12(7): 2920-2949.
Hanker LC, El-Balat A, Drosos Z, Kommoss S, Karn T, Holtrich U, et al. Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer. Journal of Cancer Research and Clinical Oncology, (2021); 147(5): 1421-1430.
Hii LW, Chung FF, Mai CW, Ng PY, Leong CO. Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells. Frontiers in Molecular Biosciences, (2021); 8: 748470.
Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacological Reviews, (2008); 60(2): 181-195.
Wang P, Yuan Y, Lin W, et al. Roles of sphingosine-1-phosphate signaling in cancer. Cancer Cell International, (2019); 19: 295.
Xiao S, Peng K, Li C, Long Y, Yu Q. The role of sphingosine-1-phosphate in autophagy and related disorders. Cell Death & Disease, (2023); 9(1): 380.
Wang X, Sun Y, Peng X, Naqvi SMAS, Yang Y, Zhang J, et al. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target. Cancer Control, (2020); 27(1): 1073274820976664.
Alkafaas SS, Elsalahaty MI, Ismail DF, Radwan MA, Elkafas SS, Loutfy SA, et al. The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target. Cancer Cell International, (2024); 24(1): 89.
Alshaker H, Thrower H, Pchejetski D. Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target. Frontiers in Oncology, (2020); 10: 289.
Datta A, Loo SY, Huang B, Wong L, Tan SS, Tan TZ, et al. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget, (2014); 5(15): 5920-5933.
Zhu YJ, You H, Tan JX, Li F, Qiu Z, Li HZ, et al. Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer. Oncology Letters, (2017); 14(1): 63-72.
Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, (2012); 106(8): 1453-1459.
Maczis MA, Maceyka M, Waters MR, Newton J, Singh M, Rigsby MF, et al. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer. Journal of Lipid Research, (2018); 59(12): 2297-2307.
Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, et al. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Research, (2019); 79(16): 4211-4226.
Rodriguez YI, Campos LE, Castro MG, Aladhami A, Oskeritzian CA, & Alvarez SE. Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment. Frontiers in Oncology, (2016); 6: 218.
Liu SQ, Xu CY, Wu WH, Fu ZH, He SW, Qin MB, et al. Sphingosine kinase 1 promotes the metastasis of colorectal cancer by inducing the epithelial-mesenchymal transition mediated by the FAK/AKT/MMPs axis. International Journal of Oncology, (2019); 54(1): 41-52.
Asma ST, Acaroz U, Imre K, Morar A, Shah SRA, Hussain SZ, et al. Natural products/bioactive compounds as a source of anticancer drugs. Cancers, (2022); 14(24): 6203.
Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, et al. Anticancer drug discovery based on natural products: From computational approaches to clinical studies. Biomedicines, (2024); 12(1): 201.
Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, et al. Natural products as anticancer agents: Current status and future perspectives. Molecules, (2022); 27(23): 8367.
Patel AA, Alothaid H, Mallick AK, Alalawy AI, Mirdad RT, Mirdad MT, et al. Inhibiting cancer progression through targeting HDAC2 with novel ligands: A dynamic insight through virtual screening and simulation. Indian Journal of Pharmaceutical Education and Research, (2024); 58(3): 802-813.
Tarique M, Ahmad S, Malik A, Ahmad I, Saeed M, Almatroudi A, et al. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and other coronaviruses: A genome-wide comparative annotation and analysis. Molecular and Cellular Biochemistry, (2023); 476: 2203-2217.
Malik A, Afaq S, El Gamal B, Abd Ellatif M, Hassan WN, Dera A, et al. Molecular docking and pharmacokinetic evaluation of natural compounds as targeted inhibitors against Crz1 protein in Rhizoctonia solani. BioMed Research International, (2023); 2562950.
Chen X, Xue B, Wahab S, Sultan A, Khalid M, Yang S. Structure-based molecular docking and molecular dynamics simulations study for the identification of dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Journal of Biomolecular Structure and Dynamics, (2025); 43(3): 1445-1458.
Faisal Z, Mazhar A, Batool SA, Akram N, Hassan M, Khan MU, et al. Exploring the multimodal health-promoting properties of resveratrol: A comprehensive review. Food Science & Nutrition, (2024); 12(4): 2240-2258.
Farhan M, Rizvi A. The pharmacological properties of red grape polyphenol resveratrol: Clinical trials and obstacles in drug development. Nutrients, (2023); 15(20): 4486.
Jang JY, Im E, Kim ND. Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: A review. International Journal of Molecular Sciences, (2022); 23(22): 13689.
Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, et al. Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Letter, (2021); 515: 63-72.
Singh CK, George J, Ahmad N. Resveratrol-based combinatorial strategies for cancer management. Annals of the New York Academy of Sciences, (2013); 1290(1): 113-121.
Brockmueller A, Buhrmann C, Shayan P, Shakibaei M. Resveratrol induces apoptosis by modulating the reciprocal crosstalk between p53 and Sirt-1 in the CRC tumor microenvironment. Frontiers in Immunology, (2023); 14: 1225530.
Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS. Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. The American Journal of Pathology, (2010); 177(1): 481-492.
Song B, Wang W, Tang X, Goh RMW, Thuya WL, Ho PCL, et al. Inhibitory potential of resveratrol in cancer metastasis: From biology to therapy. Cancers, (2023); 15(10): 2758.
Tsai HY, Ho CT, Chen YK. Biological actions and molecular effects of resveratrol, pterostilbene, and 3′-hydroxypterostilbene. Journal of Food and Drug Analysis, (2017); 25(1): 134-147.
Huang YL, Huang WP, Lee H. Roles of sphingosine 1-phosphate on tumorigenesis. World Journal of Biological Chemistry, (2011); 2(2): 25-34.
Baier A, Szyszka R. Compounds from natural sources as protein kinase inhibitors. Biomolecules, (2020); 10(11): 1546.
Thompson HJ, Lutsiv T. Natural products in precision oncology: Plant-based small molecule inhibitors of protein kinases for cancer chemoprevention. Nutrients, (2023); 15(5): 1192.
Chen X, Xue B, Wahab S, Sultan A, Khalid M, Yang S. Structure-based molecular docking and molecular dynamics simulations study for the identification of dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Journal of Biomolecular Structure and Dynamics, (2025); 43(3): 1445-1458.
Ahmad M, Das P, Ali R, Husain SA, Sultan A. Molecular docking, MD simulation and MM/GBSA predicted natural triterpene compound Ursolic Acid as a potential inhibitor of mitotic arrest deficient 2 like 1 (MAD2L1) for the therapeutics of celiac disease. Biochemical and Cellular Archives, (2024); 24(2): 1557-1570.
Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research, (2019); 47(W1): W357-W364.
Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Research, (2014); 42(Web Server issue): W32-W38.
Bibi Z. Role of cytochrome P450 in drug interactions. Nutrition & Metabolism, (2008); 5: 27.
Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harbor Protocols, (2018); 2018(6): pdb. prot095505.
Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. International Journal of Molecular Sciences, (2021); 22(23): 12827.
Hoogstraten CA, Smeitink JAM, Russel FG, Schirris TJJ. Dissecting drug-induced cytotoxicity and metabolic dysfunction in conditionally immortalized human proximal tubule cells. Frontiers in Toxicology, (2022); 4: 842396.
Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nature Chemical Biology, (2013); 9(4): 232-240.
Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: Principles, progress, and challenges. Pharmacological Reviews, (2020); 72(4): 862-898.
Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y, et al. The role of artificial intelligence in drug screening, drug design, and clinical trials. Frontiers in Pharmacology, (2024); 15: 1459954.
Smyth LA, Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. Journal of Biological Chemistry, (2009); 2(3): 131-51.
Haubrich BA, Swinney DC. Enzyme activity assays for protein kinases: Strategies to identify active substrates. Current Drug Discovery Technologies, (2016); 13(1): 2-15.
Wang Z, Min X, Xiao SH, Johnstone S, Romanow W, Meininger D, Xu H, Liu J, Dai J, An S, Thibault S, Walker N. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure, (2013); 21(5): 798-809.
Watson NA, Cartwright TN, Lawless C, Cámara-Donoso M, Sen O, Sako K, et al. Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites. Nature Communications, (2020); 11(1): 1684.
DOI: https://doi.org/10.62940/als.v13i1.3835
Refbacks
- There are currently no refbacks.